13-May-2005 - PerkinElmer, Inc.

PerkinElmer and University of Copenhagen Announce Licensing Agreement for New Maternal Health Marker ADAM12

PerkinElmer Inc. has entered into a global licensing agreement with the University of Copenhagen in Copenhagen, Denmark, to develop assay kits for the biochemical marker ADAM12. ADAM12 has broad potential in maternal health screening as a marker for fetal chromosomal abnormalities as well as for intrauterine growth retardation (IUGR) and pre-eclampsia, both of which can result in, maternal, fetal and long-term complications if left undiagnosed.

The license agreement covers exclusivity in North America and co-exclusivity in Europe, Central and South America. Kits will be developed for the complete portfolio of PerkinElmer platforms, including AutoDELFIA, DELFIA Xpress and manual DELFIA platforms.

A team consisting of Dr. Ulla Wewer at the University of Copenhagen, Dr. Michael Christiansen from Statens Serum Institut (SSI) and Dr. Kevin Spencer at the Harold Wood Hospital in England have done all of the groundwork and tested ADAM12 in several thousand samples from pregnant women to investigate its importance for prediction of chromosomal disorders.

ADAM12 also shows potential to provide an early indicator of IUGR and pre-eclampsia, for which there are no current screening mechanisms. Early studies at the University of Copenhagen, SSI and Harold Wood have shown that ADAM12 levels were reduced at 10-14 weeks in pregnancies that developed pre-eclampsia and were greatly reduced in those exhibiting both pre-eclampsia and low birth weight.

Facts, background information, dossiers
  • license agreements
  • Denmark
More about PerkinElmer
  • News

    PerkinElmer Announces Leadership Succession Plan

    PerkinElmer, Inc. announced that after a career of more than 20 years at the Company, including the last 12 years as chief executive officer, Robert F. Friel, has decided to retire as chairman and CEO and member of the board of directors as of the end of the Company’s fiscal year on Decembe ... more

    PerkinElmer appoints President & Chief Operating Officer

    PerkinElmer announced that its board of directors has named Prahlad Singh president and chief operating officer, effective January 1, 2019. In his expanded position, Dr. Singh will have responsibility for both the Discovery and Analytical Solutions (DAS) and Diagnostics operating divisions ... more

    PerkinElmer appoints Chief Financial Officer

    PerkinElmer, Inc. announced the appointment of James M. Mock to senior vice president and chief financial officer (CFO), effective May 1, 2018. Andy Wilson, PerkinElmer’s current senior vice president and CFO, who previously announced his retirement from PerkinElmer, will remain with the Co ... more

  • Companies

    PerkinElmer, Inc.

    PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. Combining operational excellence and technology expertise with an intimate understanding of its customers' needs, PerkinElmer provides produ ... more